| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Coronary Syndrome | 181 | 2023 | 2365 | 12.680 |
Why?
|
| Platelet Aggregation Inhibitors | 205 | 2023 | 3200 | 11.320 |
Why?
|
| Myocardial Infarction | 416 | 2024 | 11890 | 10.020 |
Why?
|
| Angina, Unstable | 123 | 2021 | 926 | 9.080 |
Why?
|
| Cholesterol, LDL | 91 | 2024 | 2420 | 8.640 |
Why?
|
| Anticholesteremic Agents | 67 | 2023 | 987 | 8.100 |
Why?
|
| Ticlopidine | 100 | 2017 | 895 | 7.630 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 126 | 2024 | 3332 | 7.550 |
Why?
|
| Thrombolytic Therapy | 145 | 2016 | 2108 | 5.610 |
Why?
|
| Fibrinolytic Agents | 106 | 2023 | 2167 | 5.270 |
Why?
|
| Atrial Fibrillation | 56 | 2023 | 5209 | 4.800 |
Why?
|
| Cardiovascular Diseases | 147 | 2024 | 15760 | 4.430 |
Why?
|
| Anticoagulants | 65 | 2023 | 4897 | 4.390 |
Why?
|
| Pravastatin | 48 | 2017 | 393 | 4.340 |
Why?
|
| Angioplasty, Balloon, Coronary | 94 | 2012 | 1880 | 4.110 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 33 | 2023 | 379 | 3.970 |
Why?
|
| Heptanoic Acids | 48 | 2015 | 347 | 3.950 |
Why?
|
| Coronary Artery Disease | 79 | 2024 | 6659 | 3.810 |
Why?
|
| Coronary Disease | 85 | 2021 | 5991 | 3.720 |
Why?
|
| Adenosine | 42 | 2017 | 834 | 3.720 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 56 | 2016 | 638 | 3.640 |
Why?
|
| Diabetes Mellitus, Type 2 | 91 | 2024 | 12289 | 3.550 |
Why?
|
| Simvastatin | 29 | 2021 | 352 | 3.470 |
Why?
|
| Dyslipidemias | 21 | 2022 | 895 | 3.390 |
Why?
|
| Warfarin | 26 | 2021 | 1518 | 3.370 |
Why?
|
| Hypercholesterolemia | 24 | 2023 | 1155 | 3.210 |
Why?
|
| Antithrombins | 9 | 2020 | 313 | 3.180 |
Why?
|
| Atherosclerosis | 37 | 2024 | 3518 | 3.050 |
Why?
|
| Aspirin | 80 | 2021 | 3364 | 3.020 |
Why?
|
| Hemorrhage | 59 | 2022 | 3599 | 2.990 |
Why?
|
| Diclofenac | 12 | 2013 | 67 | 2.950 |
Why?
|
| Pyrroles | 48 | 2015 | 1137 | 2.900 |
Why?
|
| Guideline Adherence | 54 | 2024 | 2283 | 2.640 |
Why?
|
| Myocardial Revascularization | 47 | 2021 | 841 | 2.540 |
Why?
|
| Hypolipidemic Agents | 23 | 2021 | 626 | 2.520 |
Why?
|
| Drug Therapy, Combination | 90 | 2023 | 6498 | 2.500 |
Why?
|
| Electrocardiography | 96 | 2018 | 6415 | 2.400 |
Why?
|
| Uracil | 16 | 2020 | 207 | 2.340 |
Why?
|
| Myocardial Reperfusion | 27 | 2017 | 347 | 2.320 |
Why?
|
| Critical Pathways | 15 | 2022 | 475 | 2.270 |
Why?
|
| Sulfones | 11 | 2011 | 447 | 2.260 |
Why?
|
| Piperidines | 25 | 2020 | 1650 | 2.230 |
Why?
|
| Double-Blind Method | 140 | 2024 | 12427 | 2.210 |
Why?
|
| Stroke | 80 | 2023 | 9952 | 2.130 |
Why?
|
| Renal Insufficiency, Chronic | 24 | 2024 | 2290 | 1.980 |
Why?
|
| Practice Guidelines as Topic | 80 | 2024 | 7475 | 1.940 |
Why?
|
| Treatment Outcome | 308 | 2024 | 64981 | 1.890 |
Why?
|
| Humans | 952 | 2024 | 760613 | 1.880 |
Why?
|
| Serine Proteinase Inhibitors | 4 | 2019 | 179 | 1.870 |
Why?
|
| Aged | 476 | 2024 | 169143 | 1.790 |
Why?
|
| Middle Aged | 525 | 2024 | 220359 | 1.750 |
Why?
|
| Secondary Prevention | 38 | 2021 | 1548 | 1.730 |
Why?
|
| Heart Failure | 79 | 2024 | 11848 | 1.710 |
Why?
|
| Platelet Function Tests | 14 | 2016 | 303 | 1.690 |
Why?
|
| Male | 602 | 2024 | 359718 | 1.640 |
Why?
|
| Registries | 85 | 2024 | 8458 | 1.640 |
Why?
|
| Thrombosis | 33 | 2022 | 3051 | 1.620 |
Why?
|
| Risk Assessment | 144 | 2024 | 24102 | 1.610 |
Why?
|
| Cholesterol Ester Transfer Proteins | 10 | 2017 | 113 | 1.600 |
Why?
|
| Oxazolidinones | 9 | 2022 | 97 | 1.580 |
Why?
|
| Female | 606 | 2024 | 391246 | 1.570 |
Why?
|
| Azetidines | 6 | 2015 | 141 | 1.520 |
Why?
|
| Randomized Controlled Trials as Topic | 104 | 2024 | 10343 | 1.500 |
Why?
|
| Pyridines | 16 | 2017 | 2879 | 1.470 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 12 | 2013 | 2282 | 1.440 |
Why?
|
| Oximes | 17 | 2021 | 306 | 1.410 |
Why?
|
| Heparin | 31 | 2010 | 1652 | 1.370 |
Why?
|
| Coronary Artery Bypass | 31 | 2016 | 2272 | 1.370 |
Why?
|
| Benzaldehydes | 14 | 2021 | 59 | 1.350 |
Why?
|
| American Heart Association | 26 | 2018 | 1081 | 1.310 |
Why?
|
| Antibodies, Monoclonal | 26 | 2023 | 9185 | 1.300 |
Why?
|
| Blood Platelets | 23 | 2018 | 2519 | 1.300 |
Why?
|
| C-Reactive Protein | 42 | 2018 | 3839 | 1.300 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 7 | 2013 | 321 | 1.290 |
Why?
|
| Risk Factors | 205 | 2024 | 74333 | 1.280 |
Why?
|
| Thromboembolism | 9 | 2020 | 1016 | 1.250 |
Why?
|
| Tyrosine | 25 | 2016 | 1438 | 1.230 |
Why?
|
| Hypoglycemic Agents | 32 | 2024 | 3149 | 1.200 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 11 | 2022 | 334 | 1.190 |
Why?
|
| Stents | 31 | 2021 | 3303 | 1.170 |
Why?
|
| Tissue Plasminogen Activator | 37 | 2017 | 1190 | 1.160 |
Why?
|
| Hospitalization | 65 | 2024 | 10789 | 1.140 |
Why?
|
| Cholesterol, HDL | 18 | 2022 | 1817 | 1.130 |
Why?
|
| Osteoarthritis | 8 | 2011 | 1055 | 1.120 |
Why?
|
| Diabetic Nephropathies | 11 | 2024 | 988 | 1.110 |
Why?
|
| Myocardial Ischemia | 26 | 2018 | 2164 | 1.110 |
Why?
|
| Cardiology | 15 | 2020 | 1723 | 1.110 |
Why?
|
| Coronary Thrombosis | 17 | 2018 | 486 | 1.100 |
Why?
|
| Dose-Response Relationship, Drug | 63 | 2020 | 10826 | 1.100 |
Why?
|
| Pyrazoles | 8 | 2017 | 1999 | 1.090 |
Why?
|
| Lipoprotein(a) | 7 | 2024 | 499 | 1.080 |
Why?
|
| Angina Pectoris | 16 | 2010 | 969 | 1.070 |
Why?
|
| Clinical Trials as Topic | 62 | 2018 | 8055 | 1.020 |
Why?
|
| Purinergic P2 Receptor Antagonists | 7 | 2010 | 72 | 1.010 |
Why?
|
| Natriuretic Peptide, Brain | 29 | 2023 | 1716 | 1.000 |
Why?
|
| Cyclooxygenase Inhibitors | 6 | 2009 | 364 | 0.990 |
Why?
|
| Lipids | 15 | 2023 | 3336 | 0.990 |
Why?
|
| Adrenergic beta-Antagonists | 20 | 2023 | 1259 | 0.980 |
Why?
|
| Syndrome | 54 | 2021 | 3280 | 0.980 |
Why?
|
| Glycosides | 5 | 2024 | 111 | 0.980 |
Why?
|
| Medication Adherence | 16 | 2022 | 2165 | 0.960 |
Why?
|
| Receptor, Cannabinoid, CB1 | 6 | 2008 | 138 | 0.950 |
Why?
|
| Diabetic Cardiomyopathies | 4 | 2018 | 96 | 0.940 |
Why?
|
| Time Factors | 125 | 2024 | 40139 | 0.930 |
Why?
|
| Cardiovascular System | 6 | 2021 | 850 | 0.920 |
Why?
|
| Coronary Angiography | 76 | 2017 | 4563 | 0.910 |
Why?
|
| Diabetic Angiopathies | 15 | 2024 | 822 | 0.900 |
Why?
|
| Drug-Eluting Stents | 10 | 2020 | 757 | 0.890 |
Why?
|
| Troponin I | 21 | 2020 | 638 | 0.890 |
Why?
|
| Receptors, Purinergic P2Y12 | 8 | 2016 | 124 | 0.880 |
Why?
|
| Hypertension | 25 | 2023 | 8595 | 0.860 |
Why?
|
| Peptide Fragments | 23 | 2023 | 5132 | 0.850 |
Why?
|
| Administration, Oral | 33 | 2021 | 4035 | 0.850 |
Why?
|
| Primary Prevention | 9 | 2021 | 1207 | 0.840 |
Why?
|
| Pyrrolidines | 20 | 2010 | 340 | 0.830 |
Why?
|
| Diabetes Mellitus | 23 | 2024 | 5890 | 0.830 |
Why?
|
| United States | 130 | 2023 | 72448 | 0.820 |
Why?
|
| Acute Disease | 66 | 2012 | 7268 | 0.810 |
Why?
|
| Troponin T | 16 | 2022 | 774 | 0.810 |
Why?
|
| Glomerular Filtration Rate | 20 | 2022 | 2180 | 0.810 |
Why?
|
| Arthritis | 5 | 2011 | 666 | 0.800 |
Why?
|
| Influenza Vaccines | 5 | 2022 | 766 | 0.800 |
Why?
|
| Quality of Health Care | 21 | 2015 | 4360 | 0.800 |
Why?
|
| Proprotein Convertases | 3 | 2023 | 97 | 0.790 |
Why?
|
| Drug Administration Schedule | 25 | 2021 | 4899 | 0.790 |
Why?
|
| Coronary Circulation | 30 | 2014 | 1577 | 0.790 |
Why?
|
| Proportional Hazards Models | 49 | 2024 | 12531 | 0.770 |
Why?
|
| Research Design | 21 | 2018 | 6180 | 0.770 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 17 | 2023 | 1523 | 0.770 |
Why?
|
| Troponin | 10 | 2011 | 516 | 0.760 |
Why?
|
| Proton Pump Inhibitors | 8 | 2020 | 551 | 0.740 |
Why?
|
| Growth Differentiation Factor 15 | 9 | 2023 | 196 | 0.730 |
Why?
|
| Benzimidazoles | 4 | 2020 | 858 | 0.730 |
Why?
|
| Evidence-Based Medicine | 29 | 2020 | 3696 | 0.720 |
Why?
|
| Blood Coagulation | 9 | 2020 | 1157 | 0.710 |
Why?
|
| Platelet Aggregation | 11 | 2012 | 805 | 0.700 |
Why?
|
| Follow-Up Studies | 90 | 2021 | 39262 | 0.690 |
Why?
|
| Chlamydophila Infections | 3 | 2005 | 22 | 0.690 |
Why?
|
| Pyridones | 2 | 2017 | 792 | 0.690 |
Why?
|
| Albuminuria | 5 | 2022 | 659 | 0.690 |
Why?
|
| Antihypertensive Agents | 12 | 2022 | 2061 | 0.690 |
Why?
|
| Quality Assurance, Health Care | 15 | 2013 | 2176 | 0.680 |
Why?
|
| Cardiovascular Agents | 12 | 2019 | 866 | 0.680 |
Why?
|
| Bone Neoplasms | 11 | 2014 | 2531 | 0.680 |
Why?
|
| Graft Occlusion, Vascular | 4 | 2021 | 560 | 0.670 |
Why?
|
| Gastrointestinal Hemorrhage | 9 | 2016 | 1131 | 0.660 |
Why?
|
| Hypertriglyceridemia | 1 | 2023 | 316 | 0.660 |
Why?
|
| Drug Costs | 7 | 2020 | 1185 | 0.660 |
Why?
|
| Thrombin | 6 | 2011 | 593 | 0.660 |
Why?
|
| Hospital Mortality | 40 | 2017 | 5418 | 0.650 |
Why?
|
| Survival Rate | 58 | 2020 | 12810 | 0.640 |
Why?
|
| Survival Analysis | 44 | 2021 | 10185 | 0.640 |
Why?
|
| Renal Insufficiency | 7 | 2023 | 820 | 0.640 |
Why?
|
| Hirudins | 7 | 2010 | 194 | 0.640 |
Why?
|
| Incidence | 51 | 2024 | 21391 | 0.630 |
Why?
|
| Drug Tolerance | 2 | 2019 | 369 | 0.630 |
Why?
|
| Prognosis | 78 | 2024 | 29661 | 0.620 |
Why?
|
| Point-of-Care Systems | 6 | 2015 | 1204 | 0.620 |
Why?
|
| Hospitals | 16 | 2016 | 3928 | 0.620 |
Why?
|
| Influenza, Human | 5 | 2022 | 1528 | 0.610 |
Why?
|
| Prospective Studies | 79 | 2023 | 54306 | 0.610 |
Why?
|
| Blood Pressure | 11 | 2023 | 8525 | 0.590 |
Why?
|
| Risk | 31 | 2020 | 9632 | 0.590 |
Why?
|
| Object Attachment | 1 | 2020 | 324 | 0.580 |
Why?
|
| Drug Resistance | 10 | 2017 | 1617 | 0.570 |
Why?
|
| Immunoglobulin Fab Fragments | 13 | 2016 | 465 | 0.560 |
Why?
|
| Patient Selection | 22 | 2024 | 4279 | 0.550 |
Why?
|
| Patient Care | 3 | 2013 | 624 | 0.550 |
Why?
|
| Multivariate Analysis | 46 | 2017 | 12159 | 0.550 |
Why?
|
| Chlamydophila pneumoniae | 4 | 2005 | 52 | 0.550 |
Why?
|
| Kidney | 17 | 2024 | 7064 | 0.530 |
Why?
|
| Blood Pressure Determination | 3 | 2018 | 640 | 0.530 |
Why?
|
| Thiophenes | 4 | 2013 | 587 | 0.530 |
Why?
|
| Recurrence | 48 | 2020 | 8483 | 0.530 |
Why?
|
| Lipid Metabolism | 5 | 2020 | 1902 | 0.530 |
Why?
|
| Gastrointestinal Diseases | 5 | 2013 | 1189 | 0.520 |
Why?
|
| Alanine | 20 | 2010 | 606 | 0.520 |
Why?
|
| Apolipoprotein B-100 | 2 | 2016 | 155 | 0.520 |
Why?
|
| Education, Medical, Continuing | 6 | 2017 | 830 | 0.510 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 4 | 2013 | 435 | 0.510 |
Why?
|
| Arteriosclerosis | 4 | 2015 | 1064 | 0.510 |
Why?
|
| Kaplan-Meier Estimate | 31 | 2020 | 6544 | 0.510 |
Why?
|
| Endocannabinoids | 2 | 2007 | 111 | 0.500 |
Why?
|
| Protease Inhibitors | 1 | 2019 | 755 | 0.500 |
Why?
|
| Lomustine | 1 | 2015 | 60 | 0.500 |
Why?
|
| Aged, 80 and over | 73 | 2023 | 58980 | 0.500 |
Why?
|
| Societies, Medical | 14 | 2020 | 3905 | 0.490 |
Why?
|
| Histiocytic Sarcoma | 1 | 2015 | 41 | 0.490 |
Why?
|
| Vascular Patency | 15 | 2010 | 901 | 0.470 |
Why?
|
| Diabetes Complications | 4 | 2018 | 1341 | 0.470 |
Why?
|
| Dog Diseases | 1 | 2015 | 141 | 0.470 |
Why?
|
| Multicenter Studies as Topic | 16 | 2022 | 1722 | 0.460 |
Why?
|
| Brain Ischemia | 4 | 2022 | 3127 | 0.460 |
Why?
|
| Fluoroquinolones | 7 | 2007 | 308 | 0.460 |
Why?
|
| Angiotensin Receptor Antagonists | 9 | 2023 | 1031 | 0.460 |
Why?
|
| beta-Alanine | 2 | 2011 | 82 | 0.450 |
Why?
|
| Metformin | 4 | 2023 | 912 | 0.450 |
Why?
|
| Odds Ratio | 36 | 2019 | 9716 | 0.440 |
Why?
|
| Arthritis, Rheumatoid | 6 | 2011 | 3763 | 0.440 |
Why?
|
| Triglycerides | 6 | 2015 | 2476 | 0.440 |
Why?
|
| Partial Thromboplastin Time | 8 | 2010 | 206 | 0.430 |
Why?
|
| Platelet Activation | 8 | 2016 | 660 | 0.430 |
Why?
|
| Language | 2 | 2012 | 1533 | 0.430 |
Why?
|
| Fenofibrate | 2 | 2016 | 88 | 0.430 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 2 | 2011 | 253 | 0.420 |
Why?
|
| Lipoproteins | 1 | 2017 | 882 | 0.420 |
Why?
|
| Heparin, Low-Molecular-Weight | 9 | 2011 | 345 | 0.420 |
Why?
|
| Risk Reduction Behavior | 9 | 2020 | 1109 | 0.420 |
Why?
|
| Combined Modality Therapy | 19 | 2020 | 8552 | 0.410 |
Why?
|
| Emergency Medical Services | 10 | 2009 | 1925 | 0.410 |
Why?
|
| Age Factors | 43 | 2021 | 18413 | 0.410 |
Why?
|
| Retrospective Studies | 75 | 2024 | 80345 | 0.400 |
Why?
|
| Hypoglycemia | 5 | 2024 | 888 | 0.400 |
Why?
|
| Sex Factors | 29 | 2021 | 10546 | 0.400 |
Why?
|
| Obesity | 12 | 2013 | 12919 | 0.400 |
Why?
|
| Safety | 7 | 2019 | 1148 | 0.400 |
Why?
|
| Medication Errors | 4 | 2002 | 784 | 0.400 |
Why?
|
| Cause of Death | 12 | 2021 | 3725 | 0.400 |
Why?
|
| Cost Sharing | 4 | 2020 | 410 | 0.390 |
Why?
|
| Kidney Diseases | 8 | 2023 | 2093 | 0.390 |
Why?
|
| Fasting | 1 | 2017 | 1603 | 0.380 |
Why?
|
| Patient Care Planning | 5 | 2019 | 908 | 0.380 |
Why?
|
| Coronary Restenosis | 3 | 2010 | 426 | 0.380 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 2011 | 27 | 0.380 |
Why?
|
| Length of Stay | 12 | 2022 | 6476 | 0.370 |
Why?
|
| Disease Management | 11 | 2024 | 2514 | 0.370 |
Why?
|
| Omeprazole | 4 | 2016 | 112 | 0.370 |
Why?
|
| Clinical Trials, Phase III as Topic | 6 | 2019 | 861 | 0.370 |
Why?
|
| Blood Glucose | 8 | 2018 | 6379 | 0.370 |
Why?
|
| Kidney Failure, Chronic | 7 | 2024 | 2470 | 0.370 |
Why?
|
| Premedication | 3 | 2007 | 253 | 0.370 |
Why?
|
| Niacin | 2 | 2010 | 119 | 0.370 |
Why?
|
| Quality Improvement | 13 | 2020 | 3835 | 0.370 |
Why?
|
| Inpatients | 5 | 2015 | 2580 | 0.360 |
Why?
|
| Patient Discharge | 14 | 2014 | 3474 | 0.360 |
Why?
|
| Mortality | 9 | 2021 | 2916 | 0.360 |
Why?
|
| Daptomycin | 1 | 2011 | 71 | 0.360 |
Why?
|
| Enoxaparin | 7 | 2006 | 397 | 0.360 |
Why?
|
| Heart Conduction System | 8 | 2009 | 1015 | 0.350 |
Why?
|
| Hyperlipoproteinemia Type II | 3 | 2020 | 396 | 0.350 |
Why?
|
| Cost-Benefit Analysis | 12 | 2020 | 5508 | 0.350 |
Why?
|
| Cyclooxygenase 2 | 1 | 2012 | 599 | 0.340 |
Why?
|
| Terminology as Topic | 4 | 2012 | 1535 | 0.330 |
Why?
|
| Peripheral Arterial Disease | 4 | 2024 | 1305 | 0.330 |
Why?
|
| Humerus | 2 | 2009 | 269 | 0.330 |
Why?
|
| Stroke Volume | 15 | 2024 | 5523 | 0.330 |
Why?
|
| Morpholines | 1 | 2012 | 583 | 0.330 |
Why?
|
| Prostheses and Implants | 3 | 2009 | 1273 | 0.330 |
Why?
|
| Adult | 102 | 2024 | 220007 | 0.320 |
Why?
|
| United States Food and Drug Administration | 7 | 2020 | 1677 | 0.320 |
Why?
|
| Cohort Studies | 34 | 2023 | 41337 | 0.320 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 5 | 2016 | 129 | 0.320 |
Why?
|
| Oligonucleotides | 1 | 2012 | 588 | 0.320 |
Why?
|
| Severity of Illness Index | 33 | 2019 | 15840 | 0.320 |
Why?
|
| Inflammation | 7 | 2017 | 10755 | 0.320 |
Why?
|
| Hyperglycemia | 5 | 2017 | 1380 | 0.310 |
Why?
|
| Anti-Ulcer Agents | 1 | 2009 | 113 | 0.310 |
Why?
|
| Predictive Value of Tests | 36 | 2021 | 15286 | 0.310 |
Why?
|
| Plasminogen Activators | 10 | 2004 | 199 | 0.310 |
Why?
|
| Cystatin C | 3 | 2018 | 270 | 0.310 |
Why?
|
| Chi-Square Distribution | 19 | 2018 | 3465 | 0.310 |
Why?
|
| Doxorubicin | 1 | 2015 | 2208 | 0.310 |
Why?
|
| Glucosides | 3 | 2019 | 533 | 0.310 |
Why?
|
| Vision Disorders | 1 | 2015 | 1084 | 0.300 |
Why?
|
| Hirudin Therapy | 8 | 1997 | 43 | 0.300 |
Why?
|
| Coronary Care Units | 3 | 2005 | 235 | 0.300 |
Why?
|
| Europe | 8 | 2024 | 3441 | 0.300 |
Why?
|
| Creatine Kinase, MB Form | 9 | 2014 | 211 | 0.300 |
Why?
|
| Anti-Bacterial Agents | 5 | 2011 | 7408 | 0.300 |
Why?
|
| Hyperlipidemias | 5 | 2017 | 782 | 0.300 |
Why?
|
| Comorbidity | 19 | 2021 | 10553 | 0.290 |
Why?
|
| Interleukin-6 | 5 | 2021 | 3215 | 0.290 |
Why?
|
| Creatinine | 11 | 2023 | 1904 | 0.290 |
Why?
|
| Algorithms | 10 | 2022 | 13982 | 0.290 |
Why?
|
| Health Expenditures | 5 | 2022 | 2362 | 0.290 |
Why?
|
| Logistic Models | 30 | 2019 | 13312 | 0.290 |
Why?
|
| CD40 Ligand | 5 | 2017 | 521 | 0.290 |
Why?
|
| Postoperative Hemorrhage | 3 | 2015 | 422 | 0.290 |
Why?
|
| Ventricular Dysfunction, Left | 9 | 2019 | 2128 | 0.290 |
Why?
|
| Smoking | 15 | 2016 | 9073 | 0.280 |
Why?
|
| Drug Substitution | 2 | 2019 | 296 | 0.280 |
Why?
|
| Chest Pain | 4 | 2005 | 1106 | 0.270 |
Why?
|
| Leukocyte Count | 5 | 2008 | 1599 | 0.270 |
Why?
|
| Emergency Service, Hospital | 15 | 2012 | 7818 | 0.270 |
Why?
|
| Benzhydryl Compounds | 3 | 2019 | 941 | 0.260 |
Why?
|
| Meta-Analysis as Topic | 6 | 2021 | 1376 | 0.260 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2012 | 1485 | 0.260 |
Why?
|
| Endothelium, Vascular | 4 | 2010 | 4434 | 0.260 |
Why?
|
| Intracranial Hemorrhages | 8 | 2008 | 844 | 0.250 |
Why?
|
| Benzodiazepines | 1 | 2011 | 1131 | 0.250 |
Why?
|
| Lovastatin | 1 | 2005 | 116 | 0.250 |
Why?
|
| Lipoproteins, HDL | 1 | 2010 | 667 | 0.250 |
Why?
|
| Arthroplasty, Replacement | 1 | 2009 | 310 | 0.250 |
Why?
|
| Down-Regulation | 4 | 2021 | 2913 | 0.250 |
Why?
|
| Atrial Natriuretic Factor | 6 | 2016 | 350 | 0.250 |
Why?
|
| Drug Utilization | 10 | 2019 | 1195 | 0.240 |
Why?
|
| Coronary Vessels | 11 | 2021 | 3112 | 0.240 |
Why?
|
| Smoking Cessation | 8 | 2014 | 2064 | 0.240 |
Why?
|
| Arthroplasty | 1 | 2007 | 313 | 0.240 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2008 | 498 | 0.230 |
Why?
|
| Catheter Ablation | 1 | 2017 | 2758 | 0.230 |
Why?
|
| Prosthesis Failure | 2 | 2007 | 1206 | 0.230 |
Why?
|
| Health Status | 3 | 2024 | 4082 | 0.230 |
Why?
|
| Cholesterol | 9 | 2022 | 2924 | 0.230 |
Why?
|
| Heart Diseases | 4 | 2010 | 2809 | 0.230 |
Why?
|
| Peripheral Vascular Diseases | 4 | 2009 | 515 | 0.230 |
Why?
|
| Brachial Artery | 1 | 2005 | 366 | 0.230 |
Why?
|
| Blood Chemical Analysis | 2 | 2018 | 437 | 0.230 |
Why?
|
| Injections, Subcutaneous | 5 | 2017 | 680 | 0.220 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2010 | 1796 | 0.220 |
Why?
|
| Subtilisin | 1 | 2023 | 12 | 0.220 |
Why?
|
| Dyspnea | 5 | 2023 | 1353 | 0.220 |
Why?
|
| Ischemic Attack, Transient | 4 | 2012 | 899 | 0.220 |
Why?
|
| Venous Thromboembolism | 2 | 2020 | 1864 | 0.220 |
Why?
|
| Reference Values | 11 | 2018 | 4925 | 0.220 |
Why?
|
| Drug Labeling | 2 | 2018 | 251 | 0.220 |
Why?
|
| Standard of Care | 5 | 2023 | 552 | 0.220 |
Why?
|
| Arteriolosclerosis | 1 | 2023 | 21 | 0.220 |
Why?
|
| Renal Dialysis | 2 | 2023 | 1801 | 0.220 |
Why?
|
| Range of Motion, Articular | 2 | 2009 | 1583 | 0.210 |
Why?
|
| Creatine Kinase | 10 | 2004 | 691 | 0.210 |
Why?
|
| Monte Carlo Method | 2 | 2019 | 1257 | 0.210 |
Why?
|
| Acetabulum | 1 | 2007 | 541 | 0.210 |
Why?
|
| Disease Progression | 14 | 2024 | 13505 | 0.210 |
Why?
|
| Polymorphism, Genetic | 9 | 2011 | 4286 | 0.210 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2006 | 1126 | 0.210 |
Why?
|
| Hospital Costs | 4 | 2017 | 976 | 0.210 |
Why?
|
| Glycosuria | 1 | 2022 | 44 | 0.210 |
Why?
|
| Bone Nails | 1 | 2003 | 218 | 0.200 |
Why?
|
| Thiazolidinediones | 3 | 2010 | 465 | 0.200 |
Why?
|
| Body Weight | 7 | 2022 | 4611 | 0.200 |
Why?
|
| Shoulder Joint | 1 | 2009 | 732 | 0.200 |
Why?
|
| Computers, Handheld | 1 | 2004 | 210 | 0.200 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2004 | 267 | 0.200 |
Why?
|
| Lower Extremity | 2 | 2006 | 1193 | 0.200 |
Why?
|
| Liver Diseases | 2 | 2017 | 1302 | 0.190 |
Why?
|
| Financial Support | 2 | 2020 | 116 | 0.190 |
Why?
|
| Anistreplase | 3 | 1997 | 11 | 0.190 |
Why?
|
| Metabolic Diseases | 2 | 2024 | 685 | 0.190 |
Why?
|
| Health Behavior | 3 | 2009 | 2622 | 0.190 |
Why?
|
| Atrial Flutter | 2 | 2022 | 258 | 0.190 |
Why?
|
| Socioeconomic Factors | 2 | 2024 | 7805 | 0.190 |
Why?
|
| Echinococcosis | 1 | 2001 | 31 | 0.190 |
Why?
|
| Endothelial Cells | 2 | 2012 | 3539 | 0.190 |
Why?
|
| Sarcoma | 3 | 2007 | 1786 | 0.190 |
Why?
|
| Lipoproteins, LDL | 5 | 2011 | 641 | 0.190 |
Why?
|
| Ventricular Function, Left | 6 | 2023 | 3880 | 0.190 |
Why?
|
| Myoglobin | 5 | 2002 | 159 | 0.190 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2021 | 71 | 0.180 |
Why?
|
| Placebo Effect | 4 | 2019 | 520 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2023 | 3454 | 0.180 |
Why?
|
| Emergency Medicine | 1 | 2010 | 1196 | 0.180 |
Why?
|
| Femur | 1 | 2007 | 1302 | 0.180 |
Why?
|
| Overweight | 2 | 2009 | 2421 | 0.180 |
Why?
|
| American Medical Association | 2 | 2011 | 60 | 0.180 |
Why?
|
| Healthcare Disparities | 6 | 2019 | 3386 | 0.180 |
Why?
|
| Anti-Obesity Agents | 3 | 2009 | 229 | 0.180 |
Why?
|
| Drug Evaluation | 2 | 2015 | 641 | 0.180 |
Why?
|
| Recombinant Proteins | 13 | 2017 | 6538 | 0.180 |
Why?
|
| Placebos | 3 | 2020 | 1668 | 0.170 |
Why?
|
| Self Report | 4 | 2020 | 3711 | 0.170 |
Why?
|
| Analysis of Variance | 10 | 2018 | 6238 | 0.170 |
Why?
|
| Forecasting | 6 | 2017 | 2931 | 0.170 |
Why?
|
| Hospitals, Urban | 2 | 2013 | 499 | 0.170 |
Why?
|
| Neopterin | 2 | 2011 | 56 | 0.170 |
Why?
|
| Fibrinolysis | 3 | 2011 | 332 | 0.170 |
Why?
|
| Tetrazoles | 2 | 2019 | 905 | 0.170 |
Why?
|
| Decision Support Techniques | 3 | 2018 | 2001 | 0.170 |
Why?
|
| Prevalence | 11 | 2024 | 15686 | 0.170 |
Why?
|
| Sex Characteristics | 3 | 2019 | 2629 | 0.160 |
Why?
|
| Drug Prescriptions | 6 | 2018 | 1673 | 0.160 |
Why?
|
| Clinical Protocols | 4 | 2016 | 1440 | 0.160 |
Why?
|
| Advisory Committees | 2 | 2014 | 788 | 0.160 |
Why?
|
| Soft Tissue Infections | 1 | 2001 | 168 | 0.160 |
Why?
|
| Attitude of Health Personnel | 4 | 2021 | 3865 | 0.160 |
Why?
|
| Confidence Intervals | 9 | 2016 | 2932 | 0.160 |
Why?
|
| Triage | 2 | 2005 | 987 | 0.160 |
Why?
|
| Clinical Medicine | 3 | 2004 | 145 | 0.160 |
Why?
|
| Peroxidase | 3 | 2016 | 605 | 0.160 |
Why?
|
| Economics, Medical | 1 | 1999 | 112 | 0.160 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2023 | 613 | 0.160 |
Why?
|
| Nursing, Private Duty | 1 | 1998 | 4 | 0.160 |
Why?
|
| Adiponectin | 2 | 2017 | 1114 | 0.150 |
Why?
|
| Tachycardia, Ventricular | 3 | 2016 | 1303 | 0.150 |
Why?
|
| France | 1 | 2019 | 511 | 0.150 |
Why?
|
| Heart Rate | 6 | 2019 | 4180 | 0.150 |
Why?
|
| Muscular Diseases | 2 | 2020 | 551 | 0.150 |
Why?
|
| Galectin 3 | 3 | 2020 | 240 | 0.150 |
Why?
|
| Staff Development | 2 | 2011 | 229 | 0.150 |
Why?
|
| Apolipoprotein A-I | 2 | 2010 | 297 | 0.150 |
Why?
|
| Anti-Infective Agents | 4 | 2007 | 981 | 0.150 |
Why?
|
| Pharmacology | 1 | 1998 | 99 | 0.150 |
Why?
|
| Interleukin-13 Receptor alpha1 Subunit | 1 | 2017 | 22 | 0.150 |
Why?
|
| Interleukin-18 | 1 | 2019 | 251 | 0.150 |
Why?
|
| Peptides | 7 | 2016 | 4354 | 0.150 |
Why?
|
| Health Care Surveys | 5 | 2014 | 2435 | 0.150 |
Why?
|
| Education, Nursing, Continuing | 1 | 1998 | 70 | 0.150 |
Why?
|
| Probability | 7 | 2010 | 2475 | 0.150 |
Why?
|
| Diabetic Retinopathy | 1 | 2007 | 1268 | 0.150 |
Why?
|
| Piperazines | 3 | 2013 | 2525 | 0.150 |
Why?
|
| Drug Therapy | 1 | 2021 | 504 | 0.150 |
Why?
|
| Insurance, Health | 4 | 2021 | 2501 | 0.150 |
Why?
|
| Clinical Competence | 3 | 2012 | 4783 | 0.150 |
Why?
|
| Protein Precursors | 5 | 2018 | 1134 | 0.150 |
Why?
|
| Deductibles and Coinsurance | 1 | 2020 | 316 | 0.150 |
Why?
|
| Vascular Diseases | 2 | 2018 | 1181 | 0.150 |
Why?
|
| Dyspepsia | 2 | 2016 | 118 | 0.150 |
Why?
|
| Endpoint Determination | 5 | 2013 | 597 | 0.150 |
Why?
|
| Platelet Count | 5 | 2017 | 777 | 0.150 |
Why?
|
| Treatment Failure | 5 | 2014 | 2647 | 0.150 |
Why?
|
| Databases, Factual | 4 | 2021 | 8022 | 0.150 |
Why?
|
| Sodium-Glucose Transporter 2 | 3 | 2023 | 98 | 0.140 |
Why?
|
| Acute Kidney Injury | 3 | 2020 | 1941 | 0.140 |
Why?
|
| Insulin Infusion Systems | 1 | 1999 | 217 | 0.140 |
Why?
|
| Critical Care | 3 | 2011 | 2699 | 0.140 |
Why?
|
| Colorimetry | 1 | 2017 | 153 | 0.140 |
Why?
|
| Monitoring, Physiologic | 1 | 2005 | 1784 | 0.140 |
Why?
|
| Health Personnel | 1 | 2011 | 3310 | 0.140 |
Why?
|
| Eligibility Determination | 2 | 2017 | 419 | 0.140 |
Why?
|
| Models, Biological | 1 | 2013 | 9468 | 0.140 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2022 | 1860 | 0.140 |
Why?
|
| Cardiotonic Agents | 2 | 2014 | 546 | 0.140 |
Why?
|
| Exercise Test | 4 | 2014 | 2128 | 0.140 |
Why?
|
| Fractures, Bone | 2 | 2006 | 2041 | 0.140 |
Why?
|
| Patient Admission | 4 | 2019 | 1385 | 0.140 |
Why?
|
| Fatty Liver | 1 | 2022 | 778 | 0.140 |
Why?
|
| Death, Sudden, Cardiac | 4 | 2022 | 1572 | 0.140 |
Why?
|
| Sulfonylurea Compounds | 1 | 2018 | 221 | 0.130 |
Why?
|
| Blood Proteins | 3 | 2020 | 1173 | 0.130 |
Why?
|
| Preoperative Care | 3 | 2011 | 2255 | 0.130 |
Why?
|
| Glucose | 4 | 2023 | 4350 | 0.130 |
Why?
|
| Quality Indicators, Health Care | 6 | 2020 | 1822 | 0.130 |
Why?
|
| Ventricular Fibrillation | 2 | 2009 | 539 | 0.130 |
Why?
|
| Consensus | 3 | 2020 | 3113 | 0.130 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2019 | 385 | 0.130 |
Why?
|
| Drug Approval | 2 | 2014 | 816 | 0.130 |
Why?
|
| Case-Control Studies | 11 | 2019 | 22052 | 0.130 |
Why?
|
| Patient Care Team | 2 | 2024 | 2511 | 0.130 |
Why?
|
| Program Evaluation | 3 | 2014 | 2493 | 0.120 |
Why?
|
| Research Personnel | 3 | 2004 | 582 | 0.120 |
Why?
|
| Patient Transfer | 1 | 2002 | 779 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2021 | 3985 | 0.120 |
Why?
|
| Sleep Disorders, Circadian Rhythm | 1 | 2017 | 196 | 0.120 |
Why?
|
| Drug Synergism | 3 | 2016 | 1752 | 0.120 |
Why?
|
| Immunoassay | 4 | 2010 | 746 | 0.120 |
Why?
|
| Limb Salvage | 2 | 2009 | 465 | 0.120 |
Why?
|
| Drug Monitoring | 4 | 2016 | 965 | 0.120 |
Why?
|
| Area Under Curve | 4 | 2015 | 1635 | 0.120 |
Why?
|
| Blood Flow Velocity | 7 | 2005 | 1377 | 0.120 |
Why?
|
| Circadian Rhythm | 3 | 2013 | 2570 | 0.120 |
Why?
|
| Vitamin K | 1 | 2017 | 321 | 0.120 |
Why?
|
| Computer-Assisted Instruction | 1 | 1998 | 362 | 0.120 |
Why?
|
| Isoenzymes | 8 | 2004 | 1690 | 0.120 |
Why?
|
| Physical Exertion | 1 | 2017 | 662 | 0.120 |
Why?
|
| Resistin | 1 | 2015 | 172 | 0.120 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 1994 | 49 | 0.120 |
Why?
|
| Outpatients | 3 | 2013 | 1607 | 0.120 |
Why?
|
| Statistics, Nonparametric | 7 | 2009 | 2852 | 0.120 |
Why?
|
| Atrioventricular Block | 1 | 2015 | 121 | 0.110 |
Why?
|
| Postoperative Care | 4 | 2020 | 1479 | 0.110 |
Why?
|
| Echocardiography, Stress | 1 | 2014 | 134 | 0.110 |
Why?
|
| False Positive Reactions | 3 | 2011 | 956 | 0.110 |
Why?
|
| Models, Economic | 1 | 2018 | 719 | 0.110 |
Why?
|
| Models, Organizational | 2 | 2008 | 545 | 0.110 |
Why?
|
| Adolescent | 21 | 2021 | 87809 | 0.110 |
Why?
|
| Exercise | 4 | 2017 | 5787 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2020 | 1408 | 0.110 |
Why?
|
| Natriuresis | 3 | 2022 | 105 | 0.110 |
Why?
|
| Serine Endopeptidases | 2 | 2015 | 1021 | 0.110 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2020 | 1765 | 0.110 |
Why?
|
| Diuretics | 3 | 2021 | 613 | 0.110 |
Why?
|
| Sleep | 2 | 2020 | 4750 | 0.110 |
Why?
|
| HIV | 1 | 2020 | 1579 | 0.110 |
Why?
|
| Foundations | 1 | 2013 | 97 | 0.100 |
Why?
|
| Drug Combinations | 4 | 2019 | 2025 | 0.100 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2018 | 2255 | 0.100 |
Why?
|
| North America | 3 | 2024 | 1284 | 0.100 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2015 | 459 | 0.100 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 877 | 0.100 |
Why?
|
| Pilot Projects | 7 | 2015 | 8556 | 0.100 |
Why?
|
| Curettage | 2 | 2014 | 73 | 0.100 |
Why?
|
| Data Collection | 1 | 2001 | 3315 | 0.100 |
Why?
|
| Fibroblast Growth Factors | 1 | 2018 | 869 | 0.100 |
Why?
|
| Benzamidines | 2 | 2002 | 23 | 0.100 |
Why?
|
| Nutrition Surveys | 2 | 2017 | 1725 | 0.100 |
Why?
|
| Epidemiologic Methods | 4 | 2010 | 1343 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 13627 | 0.100 |
Why?
|
| Inflammation Mediators | 2 | 2017 | 1881 | 0.100 |
Why?
|
| ROC Curve | 5 | 2015 | 3568 | 0.100 |
Why?
|
| Renin-Angiotensin System | 2 | 2014 | 738 | 0.100 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2020 | 974 | 0.100 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2024 | 1723 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 4 | 2013 | 2696 | 0.100 |
Why?
|
| Databases as Topic | 1 | 2013 | 474 | 0.100 |
Why?
|
| Ischemia | 2 | 2018 | 1893 | 0.100 |
Why?
|
| Biomedical Research | 2 | 2020 | 3426 | 0.100 |
Why?
|
| Biopharmaceutics | 1 | 2011 | 23 | 0.100 |
Why?
|
| Pregnancy Proteins | 1 | 2012 | 222 | 0.090 |
Why?
|
| Thrombocytopenia | 3 | 2006 | 1174 | 0.090 |
Why?
|
| Drug Interactions | 3 | 2010 | 1428 | 0.090 |
Why?
|
| Epoprostenol | 1 | 2012 | 248 | 0.090 |
Why?
|
| Osteotomy | 2 | 2014 | 836 | 0.090 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 3 | 2023 | 252 | 0.090 |
Why?
|
| Therapeutic Equivalency | 1 | 2011 | 136 | 0.090 |
Why?
|
| Stockings, Compression | 1 | 2011 | 37 | 0.090 |
Why?
|
| Cineangiography | 4 | 1999 | 113 | 0.090 |
Why?
|
| Time | 2 | 2010 | 545 | 0.090 |
Why?
|
| Young Adult | 14 | 2021 | 58748 | 0.090 |
Why?
|
| Patient Readmission | 3 | 2017 | 3322 | 0.090 |
Why?
|
| Drug Dosage Calculations | 1 | 2011 | 118 | 0.090 |
Why?
|
| Hernia, Hiatal | 1 | 2012 | 90 | 0.090 |
Why?
|
| Diagnosis, Differential | 6 | 2011 | 12968 | 0.090 |
Why?
|
| Acetyl-CoA C-Acetyltransferase | 1 | 2010 | 8 | 0.090 |
Why?
|
| Sodium-Glucose Transporter 1 | 2 | 2020 | 112 | 0.090 |
Why?
|
| Ambulatory Care | 2 | 2013 | 2782 | 0.090 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2010 | 45 | 0.090 |
Why?
|
| Propensity Score | 3 | 2017 | 1926 | 0.090 |
Why?
|
| Reoperation | 5 | 2014 | 4289 | 0.090 |
Why?
|
| Telemedicine | 2 | 2024 | 3018 | 0.090 |
Why?
|
| Accreditation | 1 | 2013 | 477 | 0.090 |
Why?
|
| Dogs | 1 | 2015 | 3841 | 0.090 |
Why?
|
| Sample Size | 3 | 2009 | 840 | 0.090 |
Why?
|
| Cerebrovascular Disorders | 3 | 2009 | 1501 | 0.090 |
Why?
|
| Health Surveys | 2 | 2011 | 4063 | 0.090 |
Why?
|
| Half-Life | 1 | 2011 | 652 | 0.080 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2010 | 94 | 0.080 |
Why?
|
| Anti-Retroviral Agents | 1 | 2019 | 1779 | 0.080 |
Why?
|
| Fumarates | 1 | 2010 | 131 | 0.080 |
Why?
|
| Research Report | 1 | 2013 | 370 | 0.080 |
Why?
|
| Safety Management | 2 | 2008 | 760 | 0.080 |
Why?
|
| Bradycardia | 1 | 2011 | 299 | 0.080 |
Why?
|
| Postoperative Complications | 6 | 2015 | 15679 | 0.080 |
Why?
|
| Insulin Resistance | 3 | 2008 | 3959 | 0.080 |
Why?
|
| Chronic Disease | 5 | 2017 | 9288 | 0.080 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2017 | 1518 | 0.080 |
Why?
|
| Time and Motion Studies | 1 | 2009 | 143 | 0.080 |
Why?
|
| Withholding Treatment | 1 | 2013 | 613 | 0.080 |
Why?
|
| Minnesota | 1 | 2009 | 340 | 0.080 |
Why?
|
| Life Expectancy | 2 | 2024 | 1247 | 0.080 |
Why?
|
| Integrin beta3 | 1 | 2009 | 121 | 0.080 |
Why?
|
| Streptokinase | 4 | 2017 | 187 | 0.080 |
Why?
|
| Patient Education as Topic | 3 | 2024 | 2315 | 0.080 |
Why?
|
| Hospital Planning | 1 | 2008 | 22 | 0.080 |
Why?
|
| Exocytosis | 3 | 1985 | 319 | 0.080 |
Why?
|
| Life Style | 3 | 2012 | 3898 | 0.080 |
Why?
|
| Animals | 15 | 2021 | 167960 | 0.080 |
Why?
|
| Sepsis | 2 | 2013 | 2592 | 0.080 |
Why?
|
| Linear Models | 7 | 2016 | 5877 | 0.080 |
Why?
|
| Bayes Theorem | 4 | 2010 | 2326 | 0.080 |
Why?
|
| Valine | 1 | 2010 | 409 | 0.080 |
Why?
|
| Observation | 1 | 2010 | 312 | 0.080 |
Why?
|
| Appetite Depressants | 1 | 2009 | 108 | 0.080 |
Why?
|
| Adenosine Diphosphate | 1 | 2009 | 429 | 0.080 |
Why?
|
| Diagnosis-Related Groups | 1 | 2010 | 450 | 0.080 |
Why?
|
| Models, Theoretical | 1 | 2020 | 3562 | 0.080 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2009 | 151 | 0.080 |
Why?
|
| Physicians | 2 | 2021 | 4591 | 0.080 |
Why?
|
| Hospital Charges | 1 | 2010 | 359 | 0.080 |
Why?
|
| Bioterrorism | 1 | 2009 | 144 | 0.080 |
Why?
|
| Drug Administration Routes | 1 | 2008 | 150 | 0.080 |
Why?
|
| Ultrasonography, Interventional | 4 | 2010 | 1501 | 0.080 |
Why?
|
| Hospitals, Rural | 1 | 2009 | 175 | 0.080 |
Why?
|
| Blood Coagulation Tests | 2 | 2003 | 270 | 0.070 |
Why?
|
| Proton-Translocating ATPases | 2 | 1985 | 113 | 0.070 |
Why?
|
| Vitamin B Complex | 1 | 2010 | 297 | 0.070 |
Why?
|
| Body Mass Index | 3 | 2021 | 12914 | 0.070 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 1931 | 0.070 |
Why?
|
| Amides | 1 | 2010 | 448 | 0.070 |
Why?
|
| Infusions, Intravenous | 7 | 2005 | 2235 | 0.070 |
Why?
|
| Sinoatrial Node | 1 | 2007 | 99 | 0.070 |
Why?
|
| Glycemic Index | 1 | 2010 | 396 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2015 | 3226 | 0.070 |
Why?
|
| Health Planning Guidelines | 1 | 2008 | 151 | 0.070 |
Why?
|
| Calgranulin A | 1 | 2007 | 80 | 0.070 |
Why?
|
| Cerebral Hemorrhage | 4 | 2009 | 2660 | 0.070 |
Why?
|
| Calgranulin B | 1 | 2007 | 86 | 0.070 |
Why?
|
| After-Hours Care | 1 | 2008 | 101 | 0.070 |
Why?
|
| Tuberculosis, Osteoarticular | 1 | 2007 | 26 | 0.070 |
Why?
|
| Decision Making | 2 | 2013 | 3925 | 0.070 |
Why?
|
| Patient Compliance | 3 | 2013 | 2688 | 0.070 |
Why?
|
| Receptors, Cannabinoid | 1 | 2007 | 43 | 0.070 |
Why?
|
| Apolipoproteins B | 1 | 2009 | 388 | 0.070 |
Why?
|
| Cardiac Output, Low | 2 | 2006 | 192 | 0.070 |
Why?
|
| Leptin | 1 | 2015 | 1590 | 0.070 |
Why?
|
| Hyperemia | 1 | 2008 | 221 | 0.070 |
Why?
|
| Emergency Treatment | 3 | 2012 | 498 | 0.070 |
Why?
|
| Cardiovascular Surgical Procedures | 2 | 2012 | 192 | 0.070 |
Why?
|
| Vaccination | 2 | 2022 | 3359 | 0.070 |
Why?
|
| Counseling | 2 | 2012 | 1548 | 0.070 |
Why?
|
| Sentinel Surveillance | 1 | 2008 | 293 | 0.070 |
Why?
|
| Regression Analysis | 9 | 2009 | 6359 | 0.070 |
Why?
|
| Genetic Engineering | 1 | 2012 | 933 | 0.070 |
Why?
|
| India | 2 | 2013 | 2336 | 0.070 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2009 | 629 | 0.070 |
Why?
|
| Periosteum | 1 | 2007 | 138 | 0.070 |
Why?
|
| Ambulances | 1 | 2006 | 92 | 0.070 |
Why?
|
| Forced Expiratory Volume | 1 | 2011 | 1809 | 0.070 |
Why?
|
| Longitudinal Studies | 7 | 2023 | 14494 | 0.070 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2007 | 488 | 0.070 |
Why?
|
| Injections, Intravenous | 4 | 2001 | 1385 | 0.070 |
Why?
|
| Pneumonia | 2 | 2018 | 2131 | 0.070 |
Why?
|
| Awards and Prizes | 1 | 2010 | 359 | 0.070 |
Why?
|
| Office Visits | 1 | 2010 | 597 | 0.070 |
Why?
|
| Disease-Free Survival | 4 | 2017 | 6831 | 0.070 |
Why?
|
| Amiodarone | 1 | 2007 | 218 | 0.070 |
Why?
|
| Uric Acid | 2 | 2022 | 807 | 0.070 |
Why?
|
| Emergency Medical Service Communication Systems | 1 | 2005 | 21 | 0.070 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 3442 | 0.060 |
Why?
|
| Fluorobenzenes | 1 | 2007 | 180 | 0.060 |
Why?
|
| Receptors, Cell Surface | 2 | 2008 | 2825 | 0.060 |
Why?
|
| Education | 1 | 2009 | 534 | 0.060 |
Why?
|
| Information Dissemination | 1 | 2014 | 1131 | 0.060 |
Why?
|
| Reproducibility of Results | 10 | 2008 | 20080 | 0.060 |
Why?
|
| Health Services Accessibility | 4 | 2019 | 5397 | 0.060 |
Why?
|
| Fibrin | 1 | 2008 | 505 | 0.060 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 3164 | 0.060 |
Why?
|
| Benchmarking | 2 | 2009 | 1044 | 0.060 |
Why?
|
| Biological Transport | 1 | 2010 | 2086 | 0.060 |
Why?
|
| Shock, Septic | 1 | 2012 | 760 | 0.060 |
Why?
|
| Phospholipases A | 1 | 2006 | 204 | 0.060 |
Why?
|
| Europe, Eastern | 1 | 2005 | 72 | 0.060 |
Why?
|
| Galectins | 2 | 2020 | 282 | 0.060 |
Why?
|
| Blood Urea Nitrogen | 1 | 2005 | 187 | 0.060 |
Why?
|
| Heart Arrest | 1 | 2015 | 1506 | 0.060 |
Why?
|
| Physicians, Primary Care | 1 | 2012 | 624 | 0.060 |
Why?
|
| Foreign-Body Migration | 1 | 2007 | 218 | 0.060 |
Why?
|
| Oxygen Consumption | 1 | 2011 | 1843 | 0.060 |
Why?
|
| Prosthesis Design | 2 | 2020 | 2129 | 0.060 |
Why?
|
| Endarterectomy, Carotid | 1 | 2010 | 559 | 0.060 |
Why?
|
| Radiography | 4 | 2009 | 6965 | 0.060 |
Why?
|
| Pelvic Bones | 1 | 2007 | 270 | 0.060 |
Why?
|
| Pulmonary Embolism | 2 | 2007 | 2543 | 0.060 |
Why?
|
| Venous Thrombosis | 2 | 2011 | 1300 | 0.060 |
Why?
|
| Sex Distribution | 3 | 2018 | 2294 | 0.060 |
Why?
|
| HIV Infections | 3 | 2020 | 17165 | 0.060 |
Why?
|
| Decision Trees | 1 | 2006 | 506 | 0.060 |
Why?
|
| Chondrosarcoma | 1 | 2007 | 296 | 0.060 |
Why?
|
| Behavior | 1 | 2007 | 540 | 0.060 |
Why?
|
| Up-Regulation | 3 | 2024 | 4122 | 0.060 |
Why?
|
| Sulfonamides | 2 | 2020 | 1977 | 0.060 |
Why?
|
| Appetite Regulation | 1 | 2005 | 84 | 0.060 |
Why?
|
| Quality of Life | 4 | 2024 | 13308 | 0.060 |
Why?
|
| Chemokine CCL2 | 2 | 2007 | 605 | 0.060 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2006 | 296 | 0.060 |
Why?
|
| Angioplasty | 2 | 1999 | 360 | 0.060 |
Why?
|
| Iron | 1 | 2013 | 1786 | 0.060 |
Why?
|
| Apolipoproteins | 2 | 2012 | 320 | 0.060 |
Why?
|
| Bone Transplantation | 1 | 2009 | 922 | 0.060 |
Why?
|
| Embolism, Cholesterol | 1 | 2004 | 33 | 0.060 |
Why?
|
| Endothelium | 1 | 2007 | 764 | 0.060 |
Why?
|
| Carbon Dioxide | 3 | 1985 | 1146 | 0.060 |
Why?
|
| Coronary Stenosis | 3 | 2005 | 820 | 0.060 |
Why?
|
| Carotid Artery Diseases | 1 | 2010 | 881 | 0.060 |
Why?
|
| Emergencies | 2 | 2009 | 1210 | 0.060 |
Why?
|
| Computer Simulation | 1 | 2017 | 6218 | 0.060 |
Why?
|
| Ischemic Preconditioning, Myocardial | 2 | 2001 | 69 | 0.060 |
Why?
|
| Telemetry | 1 | 2005 | 199 | 0.060 |
Why?
|
| Calcium Channel Blockers | 3 | 2022 | 694 | 0.060 |
Why?
|
| Apolipoproteins E | 1 | 2009 | 1437 | 0.060 |
Why?
|
| Acid-Base Equilibrium | 2 | 1983 | 180 | 0.060 |
Why?
|
| Heart Rupture, Post-Infarction | 1 | 2003 | 48 | 0.060 |
Why?
|
| Femoral Neoplasms | 1 | 2003 | 81 | 0.050 |
Why?
|
| Anti-HIV Agents | 1 | 2019 | 4491 | 0.050 |
Why?
|
| Tibia | 1 | 2009 | 1065 | 0.050 |
Why?
|
| Community Health Services | 1 | 2008 | 654 | 0.050 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2007 | 784 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2017 | 3802 | 0.050 |
Why?
|
| Fibrinogen | 4 | 2004 | 887 | 0.050 |
Why?
|
| Physician's Role | 2 | 2014 | 918 | 0.050 |
Why?
|
| Guidelines as Topic | 4 | 2010 | 1392 | 0.050 |
Why?
|
| Behavior Therapy | 1 | 2009 | 868 | 0.050 |
Why?
|
| Hospital Information Systems | 1 | 2005 | 394 | 0.050 |
Why?
|
| Urinary Bladder | 3 | 1985 | 1166 | 0.050 |
Why?
|
| Pulsatile Flow | 1 | 2004 | 321 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1985 | 2502 | 0.050 |
Why?
|
| Medical Records | 2 | 2006 | 1407 | 0.050 |
Why?
|
| Residence Characteristics | 2 | 2013 | 2061 | 0.050 |
Why?
|
| Internal Fixators | 1 | 2003 | 183 | 0.050 |
Why?
|
| Electronic Mail | 1 | 2024 | 213 | 0.050 |
Why?
|
| Triiodothyronine, Reverse | 1 | 1982 | 23 | 0.050 |
Why?
|
| Disaster Planning | 1 | 2008 | 558 | 0.050 |
Why?
|
| Neutrophil Activation | 1 | 2003 | 181 | 0.050 |
Why?
|
| Academic Medical Centers | 2 | 2009 | 2754 | 0.050 |
Why?
|
| Massachusetts | 4 | 2020 | 8803 | 0.050 |
Why?
|
| Equipment Design | 3 | 2008 | 3520 | 0.050 |
Why?
|
| Marijuana Abuse | 1 | 2006 | 411 | 0.050 |
Why?
|
| Systole | 2 | 2017 | 947 | 0.050 |
Why?
|
| Health Care Costs | 4 | 2016 | 3258 | 0.050 |
Why?
|
| Statistics as Topic | 5 | 2009 | 2362 | 0.050 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2007 | 749 | 0.050 |
Why?
|
| P-Selectin | 3 | 2017 | 599 | 0.050 |
Why?
|
| Pharmacists | 1 | 2024 | 259 | 0.050 |
Why?
|
| Reference Standards | 3 | 2012 | 1004 | 0.050 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2002 | 144 | 0.050 |
Why?
|
| Metabolic Clearance Rate | 4 | 2007 | 361 | 0.050 |
Why?
|
| Vasodilation | 1 | 2005 | 962 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 12628 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2014 | 9278 | 0.050 |
Why?
|
| Blood Coagulation Disorders | 1 | 2004 | 349 | 0.050 |
Why?
|
| Recovery of Function | 2 | 2009 | 2985 | 0.050 |
Why?
|
| Osteosarcoma | 1 | 2007 | 897 | 0.050 |
Why?
|
| Sensitivity and Specificity | 3 | 2011 | 14661 | 0.050 |
Why?
|
| Hemodynamics | 5 | 2015 | 4173 | 0.050 |
Why?
|
| Sweden | 2 | 2014 | 1381 | 0.050 |
Why?
|
| Hip Prosthesis | 1 | 2007 | 920 | 0.050 |
Why?
|
| Genetic Variation | 3 | 2006 | 6552 | 0.050 |
Why?
|
| Peptic Ulcer | 2 | 2016 | 219 | 0.050 |
Why?
|
| Models, Statistical | 3 | 2011 | 5075 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 11713 | 0.040 |
Why?
|
| Seasons | 2 | 2009 | 1522 | 0.040 |
Why?
|
| Referral and Consultation | 2 | 2013 | 3598 | 0.040 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2023 | 366 | 0.040 |
Why?
|
| Vaccines, Inactivated | 1 | 2021 | 180 | 0.040 |
Why?
|
| Calcium | 2 | 2021 | 5725 | 0.040 |
Why?
|
| Triiodothyronine | 1 | 1982 | 493 | 0.040 |
Why?
|
| Chlamydia Infections | 1 | 2003 | 362 | 0.040 |
Why?
|
| Disease Reservoirs | 1 | 2020 | 121 | 0.040 |
Why?
|
| Serum Amyloid A Protein | 1 | 2000 | 127 | 0.040 |
Why?
|
| Amniotic Fluid | 1 | 1982 | 378 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2006 | 1504 | 0.040 |
Why?
|
| Spironolactone | 1 | 2023 | 411 | 0.040 |
Why?
|
| Dalteparin | 1 | 1999 | 44 | 0.040 |
Why?
|
| Random Allocation | 3 | 2017 | 2394 | 0.040 |
Why?
|
| Clinical Enzyme Tests | 1 | 1999 | 114 | 0.040 |
Why?
|
| Intra-Abdominal Fat | 1 | 2005 | 607 | 0.040 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2001 | 361 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2015 | 3620 | 0.040 |
Why?
|
| District of Columbia | 1 | 2019 | 160 | 0.040 |
Why?
|
| Myocarditis | 1 | 2007 | 766 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2001 | 1628 | 0.040 |
Why?
|
| Platelet Adhesiveness | 1 | 1999 | 154 | 0.040 |
Why?
|
| Heart Rupture | 1 | 1999 | 21 | 0.040 |
Why?
|
| Product Labeling | 1 | 2020 | 77 | 0.040 |
Why?
|
| Calcinosis | 2 | 2005 | 1476 | 0.040 |
Why?
|
| Radiation Injuries | 1 | 2006 | 1183 | 0.040 |
Why?
|
| Baltimore | 1 | 2019 | 230 | 0.040 |
Why?
|
| Perioperative Care | 1 | 2007 | 1037 | 0.040 |
Why?
|
| Microcirculation | 4 | 2006 | 1278 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2022 | 674 | 0.040 |
Why?
|
| Pneumonia, Bacterial | 1 | 2002 | 319 | 0.040 |
Why?
|
| Reperfusion | 1 | 2000 | 271 | 0.040 |
Why?
|
| Anticonvulsants | 1 | 2009 | 1879 | 0.040 |
Why?
|
| Protons | 2 | 1983 | 1114 | 0.040 |
Why?
|
| Morbidity | 2 | 2016 | 1765 | 0.040 |
Why?
|
| Relative Value Scales | 1 | 1999 | 86 | 0.040 |
Why?
|
| Kidney Neoplasms | 2 | 2007 | 4312 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2010 | 1939 | 0.040 |
Why?
|
| South America | 1 | 2019 | 181 | 0.040 |
Why?
|
| Bariatric Surgery | 1 | 2009 | 1005 | 0.040 |
Why?
|
| Wound Healing | 2 | 2006 | 2788 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2009 | 3527 | 0.040 |
Why?
|
| Psychology, Educational | 1 | 1998 | 6 | 0.040 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2008 | 1387 | 0.040 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2004 | 553 | 0.040 |
Why?
|
| Transportation of Patients | 1 | 1999 | 176 | 0.040 |
Why?
|
| Heart | 2 | 2003 | 4393 | 0.040 |
Why?
|
| New Zealand | 1 | 2019 | 355 | 0.040 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2020 | 382 | 0.040 |
Why?
|
| Insulin | 2 | 2023 | 6596 | 0.040 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2007 | 1152 | 0.040 |
Why?
|
| Radionuclide Imaging | 2 | 1999 | 1975 | 0.040 |
Why?
|
| Fishes | 1 | 2021 | 601 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2011 | 3531 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2001 | 601 | 0.040 |
Why?
|
| Monocytes | 1 | 2007 | 2575 | 0.040 |
Why?
|
| Potassium | 1 | 2021 | 1313 | 0.040 |
Why?
|
| Anthropometry | 1 | 2002 | 1348 | 0.040 |
Why?
|
| Sodium | 1 | 2022 | 1594 | 0.040 |
Why?
|
| Prodrugs | 1 | 1999 | 259 | 0.040 |
Why?
|
| Mycoses | 1 | 2020 | 387 | 0.040 |
Why?
|
| Ablation Techniques | 1 | 2020 | 248 | 0.040 |
Why?
|
| Weight Loss | 1 | 2009 | 2684 | 0.040 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2020 | 257 | 0.040 |
Why?
|
| Virus Latency | 1 | 2020 | 362 | 0.040 |
Why?
|
| Asia | 1 | 2019 | 620 | 0.040 |
Why?
|
| Surgical Wound Infection | 1 | 2006 | 1527 | 0.040 |
Why?
|
| Electric Countershock | 1 | 2020 | 537 | 0.040 |
Why?
|
| Fibrinopeptide A | 1 | 1996 | 43 | 0.040 |
Why?
|
| Muscles | 1 | 2022 | 1581 | 0.040 |
Why?
|
| Regional Blood Flow | 3 | 2008 | 1490 | 0.030 |
Why?
|
| Child | 6 | 2013 | 79799 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2005 | 2773 | 0.030 |
Why?
|
| Embolism | 1 | 2020 | 408 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2009 | 2890 | 0.030 |
Why?
|
| Antifibrinolytic Agents | 1 | 2000 | 292 | 0.030 |
Why?
|
| Indians, North American | 1 | 2020 | 350 | 0.030 |
Why?
|
| Carbohydrate Metabolism | 1 | 2017 | 262 | 0.030 |
Why?
|
| Phospholipases A2 | 2 | 2007 | 197 | 0.030 |
Why?
|
| Antithrombin III | 1 | 1996 | 129 | 0.030 |
Why?
|
| Utah | 1 | 1996 | 131 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2020 | 1351 | 0.030 |
Why?
|
| Adrenomedullin | 1 | 2016 | 85 | 0.030 |
Why?
|
| Turtles | 3 | 1985 | 40 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2020 | 1342 | 0.030 |
Why?
|
| Transsexualism | 1 | 2019 | 177 | 0.030 |
Why?
|
| Prothrombin | 1 | 1996 | 191 | 0.030 |
Why?
|
| Genotype | 6 | 2010 | 12957 | 0.030 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 1 | 2016 | 60 | 0.030 |
Why?
|
| Family Practice | 1 | 1999 | 510 | 0.030 |
Why?
|
| Rhabdomyolysis | 1 | 2017 | 155 | 0.030 |
Why?
|
| Pharmacogenetics | 2 | 2010 | 680 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 422 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2021 | 843 | 0.030 |
Why?
|
| Fibrosis | 1 | 2022 | 2042 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2007 | 3016 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2012 | 4647 | 0.030 |
Why?
|
| Hernia, Diaphragmatic | 1 | 1996 | 246 | 0.030 |
Why?
|
| Neutrophils | 1 | 2008 | 3767 | 0.030 |
Why?
|
| Diastole | 1 | 2017 | 788 | 0.030 |
Why?
|
| Medicare | 2 | 2010 | 6785 | 0.030 |
Why?
|
| Australia | 1 | 2019 | 1290 | 0.030 |
Why?
|
| Life Tables | 2 | 2006 | 365 | 0.030 |
Why?
|
| Glycopeptides | 1 | 2016 | 220 | 0.030 |
Why?
|
| Hypertension, Renal | 1 | 2015 | 141 | 0.030 |
Why?
|
| Defibrillators, Implantable | 1 | 2004 | 1499 | 0.030 |
Why?
|
| Contrast Media | 3 | 2003 | 5305 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2014 | 5799 | 0.030 |
Why?
|
| Models, Cardiovascular | 2 | 2003 | 977 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2021 | 1575 | 0.030 |
Why?
|
| Hypotension | 1 | 2020 | 883 | 0.030 |
Why?
|
| Blood Coagulation Factors | 1 | 1997 | 366 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2012 | 20509 | 0.030 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 1996 | 418 | 0.030 |
Why?
|
| Biphenyl Compounds | 1 | 2019 | 992 | 0.030 |
Why?
|
| Thromboxane-A Synthase | 1 | 1993 | 34 | 0.030 |
Why?
|
| Age of Onset | 1 | 2021 | 3302 | 0.030 |
Why?
|
| Intestinal Perforation | 1 | 2016 | 250 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2014 | 369 | 0.030 |
Why?
|
| Denervation | 1 | 2015 | 277 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 1997 | 1098 | 0.030 |
Why?
|
| Diarrhea | 1 | 2020 | 1319 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2017 | 1130 | 0.030 |
Why?
|
| Myocardium | 2 | 2004 | 4700 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 1998 | 978 | 0.030 |
Why?
|
| Documentation | 1 | 2000 | 893 | 0.030 |
Why?
|
| Peptide Hydrolases | 1 | 1996 | 623 | 0.030 |
Why?
|
| Directive Counseling | 1 | 2014 | 171 | 0.030 |
Why?
|
| Fee-for-Service Plans | 1 | 1998 | 705 | 0.030 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2015 | 291 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2020 | 2698 | 0.030 |
Why?
|
| Social Stigma | 1 | 2019 | 734 | 0.030 |
Why?
|
| Matched-Pair Analysis | 1 | 2013 | 284 | 0.030 |
Why?
|
| Chemical Precipitation | 1 | 2012 | 176 | 0.030 |
Why?
|
| Naproxen | 1 | 2013 | 100 | 0.030 |
Why?
|
| Cerebral Revascularization | 1 | 2015 | 249 | 0.030 |
Why?
|
| Managed Care Programs | 1 | 1998 | 939 | 0.030 |
Why?
|
| Retreatment | 2 | 2007 | 600 | 0.030 |
Why?
|
| Ultracentrifugation | 1 | 2012 | 183 | 0.030 |
Why?
|
| Internationality | 1 | 2018 | 1004 | 0.030 |
Why?
|
| Knowledge Management | 1 | 2012 | 6 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2009 | 15790 | 0.030 |
Why?
|
| Vascular Resistance | 1 | 2015 | 933 | 0.030 |
Why?
|
| Pericardium | 3 | 2002 | 675 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2005 | 5961 | 0.030 |
Why?
|
| Germany | 1 | 2014 | 873 | 0.030 |
Why?
|
| Patient Participation | 1 | 2021 | 1439 | 0.030 |
Why?
|
| Intestinal Obstruction | 1 | 2016 | 434 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2007 | 3218 | 0.020 |
Why?
|
| Heterozygote | 2 | 2009 | 2798 | 0.020 |
Why?
|
| Dextran Sulfate | 1 | 2012 | 255 | 0.020 |
Why?
|
| Ibuprofen | 1 | 2013 | 229 | 0.020 |
Why?
|
| Haplotypes | 2 | 2009 | 2764 | 0.020 |
Why?
|
| Program Development | 1 | 1998 | 1297 | 0.020 |
Why?
|
| Intermittent Claudication | 1 | 2014 | 305 | 0.020 |
Why?
|
| Hospital Bed Capacity | 1 | 2012 | 210 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2020 | 1894 | 0.020 |
Why?
|
| Peer Review, Health Care | 1 | 2011 | 73 | 0.020 |
Why?
|
| Telecommunications | 1 | 2011 | 80 | 0.020 |
Why?
|
| Congenital Abnormalities | 1 | 1996 | 704 | 0.020 |
Why?
|
| Catalysis | 1 | 2013 | 775 | 0.020 |
Why?
|
| Tablets, Enteric-Coated | 1 | 2010 | 22 | 0.020 |
Why?
|
| Neoplasms | 3 | 2017 | 22075 | 0.020 |
Why?
|
| Cyclosporine | 1 | 1993 | 777 | 0.020 |
Why?
|
| International Cooperation | 1 | 2017 | 1433 | 0.020 |
Why?
|
| Markov Chains | 1 | 2014 | 968 | 0.020 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 1996 | 615 | 0.020 |
Why?
|
| Carotid Artery Thrombosis | 1 | 2010 | 51 | 0.020 |
Why?
|
| Fetal Diseases | 1 | 1996 | 911 | 0.020 |
Why?
|
| Diet | 1 | 2009 | 8010 | 0.020 |
Why?
|
| Mutation | 1 | 2015 | 29957 | 0.020 |
Why?
|
| Brazil | 1 | 2014 | 1212 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2012 | 613 | 0.020 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 5325 | 0.020 |
Why?
|
| Disease Susceptibility | 2 | 2007 | 1792 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2012 | 639 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2012 | 681 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 1999 | 2141 | 0.020 |
Why?
|
| Asthma | 1 | 2008 | 6172 | 0.020 |
Why?
|
| Stress, Mechanical | 2 | 2008 | 1666 | 0.020 |
Why?
|
| Goals | 1 | 2015 | 708 | 0.020 |
Why?
|
| Receptors, Purinergic P2Y1 | 1 | 2009 | 42 | 0.020 |
Why?
|
| Affect | 1 | 2017 | 1480 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 1995 | 3085 | 0.020 |
Why?
|
| Mice | 2 | 2017 | 81209 | 0.020 |
Why?
|
| Biotransformation | 1 | 2009 | 166 | 0.020 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2009 | 92 | 0.020 |
Why?
|
| Canada | 3 | 2002 | 2126 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2014 | 1008 | 0.020 |
Why?
|
| Prenatal Diagnosis | 1 | 1996 | 1264 | 0.020 |
Why?
|
| Achievement | 1 | 2010 | 289 | 0.020 |
Why?
|
| Glipizide | 1 | 2008 | 48 | 0.020 |
Why?
|
| Pregnancy | 3 | 2020 | 29746 | 0.020 |
Why?
|
| Kidney Tubules, Collecting | 1 | 1989 | 163 | 0.020 |
Why?
|
| Data Mining | 1 | 2013 | 553 | 0.020 |
Why?
|
| Extremities | 1 | 2014 | 867 | 0.020 |
Why?
|
| Learning | 1 | 1998 | 1739 | 0.020 |
Why?
|
| Connecticut | 1 | 2009 | 365 | 0.020 |
Why?
|
| Bicarbonates | 1 | 1989 | 292 | 0.020 |
Why?
|
| Public Policy | 1 | 2012 | 560 | 0.020 |
Why?
|
| Renin | 1 | 2010 | 635 | 0.020 |
Why?
|
| Alleles | 3 | 2006 | 6900 | 0.020 |
Why?
|
| Exercise Therapy | 1 | 2015 | 919 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 2012 | 759 | 0.020 |
Why?
|
| Angiography | 2 | 2004 | 1605 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 3725 | 0.020 |
Why?
|
| Biological Transport, Active | 2 | 1985 | 327 | 0.020 |
Why?
|
| Boston | 1 | 2000 | 9278 | 0.020 |
Why?
|
| Chemistry, Clinical | 1 | 2007 | 64 | 0.020 |
Why?
|
| Resuscitation | 1 | 2012 | 661 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4353 | 0.020 |
Why?
|
| Blood Vessels | 1 | 2013 | 1112 | 0.020 |
Why?
|
| Health Maintenance Organizations | 1 | 2010 | 660 | 0.020 |
Why?
|
| Evidence-Based Practice | 1 | 2012 | 496 | 0.020 |
Why?
|
| Kidney Tubules | 1 | 1989 | 449 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2004 | 10181 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2013 | 830 | 0.020 |
Why?
|
| Age Distribution | 1 | 2013 | 2893 | 0.020 |
Why?
|
| Feedback | 1 | 2011 | 791 | 0.020 |
Why?
|
| Echocardiography | 1 | 1999 | 4981 | 0.020 |
Why?
|
| Critical Illness | 2 | 2012 | 2709 | 0.020 |
Why?
|
| Antibodies | 1 | 2015 | 2421 | 0.020 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2012 | 998 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2013 | 2222 | 0.020 |
Why?
|
| Weight-Bearing | 1 | 2009 | 518 | 0.020 |
Why?
|
| Lactic Acid | 1 | 2012 | 1134 | 0.020 |
Why?
|
| Acute-Phase Reaction | 1 | 2006 | 91 | 0.020 |
Why?
|
| Shock, Cardiogenic | 3 | 1999 | 734 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2011 | 1683 | 0.020 |
Why?
|
| Patient Rights | 1 | 2007 | 125 | 0.020 |
Why?
|
| Colchicine | 2 | 1985 | 261 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2007 | 573 | 0.020 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2009 | 578 | 0.020 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1999 | 2160 | 0.020 |
Why?
|
| Hospitals, Community | 1 | 2008 | 367 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2008 | 412 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2010 | 718 | 0.020 |
Why?
|
| Cross Reactions | 1 | 2007 | 818 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2007 | 1060 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2012 | 1296 | 0.020 |
Why?
|
| Oklahoma | 1 | 2004 | 36 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2013 | 2138 | 0.020 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2004 | 24 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2012 | 1248 | 0.020 |
Why?
|
| Therapeutics | 1 | 2005 | 114 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2021 | 4371 | 0.020 |
Why?
|
| Calibration | 1 | 2007 | 816 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2020 | 4924 | 0.010 |
Why?
|
| Homozygote | 1 | 2009 | 1788 | 0.010 |
Why?
|
| Diet, Reducing | 1 | 2008 | 487 | 0.010 |
Why?
|
| Enzymes | 1 | 2006 | 261 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 1990 | 1602 | 0.010 |
Why?
|
| Case Management | 1 | 2006 | 272 | 0.010 |
Why?
|
| Erythrocyte Transfusion | 1 | 2009 | 566 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 1985 | 389 | 0.010 |
Why?
|
| Propanolamines | 1 | 2004 | 162 | 0.010 |
Why?
|
| Early Diagnosis | 1 | 2009 | 1180 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 9406 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 1993 | 13451 | 0.010 |
Why?
|
| Hematologic Agents | 1 | 2004 | 41 | 0.010 |
Why?
|
| H(+)-K(+)-Exchanging ATPase | 1 | 1983 | 36 | 0.010 |
Why?
|
| Membrane Fusion | 1 | 1985 | 266 | 0.010 |
Why?
|
| Cell Separation | 1 | 1989 | 1720 | 0.010 |
Why?
|
| Private Practice | 1 | 2004 | 152 | 0.010 |
Why?
|
| Sialoglycoproteins | 1 | 2004 | 315 | 0.010 |
Why?
|
| Lung | 1 | 1982 | 9994 | 0.010 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2005 | 220 | 0.010 |
Why?
|
| Pennsylvania | 1 | 2004 | 615 | 0.010 |
Why?
|
| von Willebrand Factor | 1 | 2007 | 673 | 0.010 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2008 | 613 | 0.010 |
Why?
|
| Carbazoles | 1 | 2004 | 220 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1993 | 17624 | 0.010 |
Why?
|
| Prejudice | 1 | 2007 | 563 | 0.010 |
Why?
|
| Pandemics | 1 | 2023 | 8623 | 0.010 |
Why?
|
| Fees, Pharmaceutical | 1 | 2002 | 66 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2004 | 298 | 0.010 |
Why?
|
| Geriatrics | 1 | 2007 | 387 | 0.010 |
Why?
|
| Medical Staff, Hospital | 1 | 2006 | 600 | 0.010 |
Why?
|
| Observer Variation | 1 | 2008 | 2601 | 0.010 |
Why?
|
| Fetal Organ Maturity | 1 | 1982 | 83 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2017 | 14374 | 0.010 |
Why?
|
| Superoxides | 1 | 2003 | 387 | 0.010 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2007 | 1110 | 0.010 |
Why?
|
| Neoplasm Staging | 2 | 2007 | 11152 | 0.010 |
Why?
|
| Antigens, Human Platelet | 1 | 2001 | 41 | 0.010 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2009 | 1032 | 0.010 |
Why?
|
| Polysaccharides | 1 | 2008 | 1016 | 0.010 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2008 | 1214 | 0.010 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2007 | 786 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2019 | 4775 | 0.010 |
Why?
|
| Minisatellite Repeats | 1 | 2002 | 164 | 0.010 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2004 | 479 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 1 | 2000 | 182 | 0.010 |
Why?
|
| Pain | 1 | 2016 | 5066 | 0.010 |
Why?
|
| Urine | 1 | 1982 | 363 | 0.010 |
Why?
|
| Intraoperative Complications | 1 | 2007 | 1186 | 0.010 |
Why?
|
| Minority Groups | 1 | 2008 | 1201 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2009 | 4815 | 0.010 |
Why?
|
| Collateral Circulation | 1 | 2001 | 292 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2004 | 1578 | 0.010 |
Why?
|
| Anemia | 1 | 2009 | 1511 | 0.010 |
Why?
|
| Amidines | 1 | 1999 | 29 | 0.010 |
Why?
|
| Rheology | 1 | 2000 | 348 | 0.010 |
Why?
|
| Government Agencies | 1 | 2000 | 161 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 2006 | 1328 | 0.010 |
Why?
|
| Leukocytosis | 1 | 2000 | 251 | 0.010 |
Why?
|
| Adenosine Triphosphatases | 1 | 1983 | 833 | 0.010 |
Why?
|
| Myocytes, Cardiac | 1 | 2008 | 1657 | 0.010 |
Why?
|
| Endocytosis | 1 | 1983 | 959 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 22020 | 0.010 |
Why?
|
| Epithelium | 1 | 1983 | 1605 | 0.010 |
Why?
|
| Nitrites | 1 | 1999 | 159 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 1993 | 4214 | 0.010 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2002 | 240 | 0.010 |
Why?
|
| Complement C4 | 1 | 1999 | 244 | 0.010 |
Why?
|
| Choice Behavior | 1 | 2004 | 821 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2001 | 1705 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 3527 | 0.010 |
Why?
|
| Heterocyclic Compounds | 1 | 1999 | 247 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2007 | 36286 | 0.010 |
Why?
|
| Infection Control | 1 | 2005 | 983 | 0.010 |
Why?
|
| Blood Sedimentation | 1 | 1999 | 234 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2008 | 5201 | 0.010 |
Why?
|
| Plasminogen | 1 | 1998 | 146 | 0.010 |
Why?
|
| Internet | 1 | 2010 | 3078 | 0.010 |
Why?
|
| Nitrates | 1 | 1999 | 264 | 0.010 |
Why?
|
| Hemorheology | 1 | 1997 | 144 | 0.010 |
Why?
|
| Information Services | 1 | 1999 | 235 | 0.010 |
Why?
|
| Antibodies, Antinuclear | 1 | 1999 | 344 | 0.010 |
Why?
|
| Orthopedic Procedures | 1 | 2007 | 1263 | 0.010 |
Why?
|
| Complement C3 | 1 | 1999 | 451 | 0.010 |
Why?
|
| Nitroglycerin | 1 | 1998 | 329 | 0.010 |
Why?
|
| Medicaid | 1 | 2010 | 2815 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2001 | 1697 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2009 | 3448 | 0.010 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 1996 | 173 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2000 | 791 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2003 | 21029 | 0.010 |
Why?
|
| Leadership | 1 | 2005 | 1371 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 2007 | 1913 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1996 | 26179 | 0.010 |
Why?
|
| Cost Control | 1 | 1998 | 630 | 0.010 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2007 | 1903 | 0.010 |
Why?
|
| Selection Bias | 1 | 1997 | 358 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2005 | 1915 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1995 | 865 | 0.010 |
Why?
|
| Autoimmunity | 1 | 2002 | 1370 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 4571 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2017 | 23374 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 1999 | 1516 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2002 | 2208 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2007 | 42056 | 0.010 |
Why?
|
| Thromboxane B2 | 1 | 1993 | 147 | 0.010 |
Why?
|
| Autoantibodies | 1 | 2002 | 2119 | 0.010 |
Why?
|
| Mental Health Services | 1 | 2005 | 1717 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2001 | 2668 | 0.010 |
Why?
|
| Hemostasis | 1 | 1996 | 468 | 0.010 |
Why?
|
| Italy | 1 | 1995 | 841 | 0.010 |
Why?
|
| Neutropenia | 1 | 1998 | 884 | 0.010 |
Why?
|
| Women's Health | 1 | 2002 | 2056 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2003 | 2221 | 0.010 |
Why?
|
| Phenotype | 1 | 2009 | 16548 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1999 | 3530 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1990 | 852 | 0.010 |
Why?
|
| 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid | 1 | 1989 | 33 | 0.010 |
Why?
|
| 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 1 | 1989 | 59 | 0.010 |
Why?
|
| DNA Probes | 1 | 1990 | 551 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1990 | 1055 | 0.010 |
Why?
|
| Capillaries | 1 | 1990 | 744 | 0.000 |
Why?
|
| Sodium Channels | 1 | 1989 | 344 | 0.000 |
Why?
|
| Immunoblotting | 1 | 1990 | 1649 | 0.000 |
Why?
|
| Research | 1 | 1995 | 1974 | 0.000 |
Why?
|
| Chlorides | 1 | 1989 | 663 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 17790 | 0.000 |
Why?
|
| Organ Specificity | 1 | 1990 | 1954 | 0.000 |
Why?
|
| Cloning, Molecular | 1 | 1990 | 4169 | 0.000 |
Why?
|
| Infant | 1 | 2007 | 36053 | 0.000 |
Why?
|
| Cattle | 1 | 1990 | 3847 | 0.000 |
Why?
|
| Cross-Sectional Studies | 1 | 2005 | 25941 | 0.000 |
Why?
|
| Cells, Cultured | 2 | 1990 | 18955 | 0.000 |
Why?
|
| Rabbits | 1 | 1989 | 4773 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1990 | 6065 | 0.000 |
Why?
|
| Cerebrovascular Circulation | 1 | 1990 | 2733 | 0.000 |
Why?
|
| Base Sequence | 1 | 1990 | 12444 | 0.000 |
Why?
|
| DNA | 1 | 1990 | 7233 | 0.000 |
Why?
|
| Cell Line | 1 | 1990 | 15620 | 0.000 |
Why?
|